AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 241 min read$UTHR

ROTHBLATT MARTINE A sold $4.9M of UTHR (indirect holdings)

ROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $518.39 ($512.71–$527.71, $4.92M total) across 15 trades on 2026-08-21 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · ROTHBLATT MARTINE A
Published Aug 24, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 24, 2026, 9:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$UTHR
Bearish
medium confidence
Mentioned
$UTHR
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$UTHRBearishLow
01

Why it matters

The disclosed sale reduces insider ownership and could be interpreted as a bearish signal, though the 10b5‑1 plan tempers speculation.

02

Market read

Primary relevance is to UTHR shareholders; limited spillover to biotech sector.

03

What to watch

CEO retains a sizable stake; sale represents <2% of holdings, may not signal major concern.

Relevance 5/10Novelty 8/10Timing: post‑market 2026‑08‑21

Background

SEC Form 4 filing discloses insider transaction for United Therapeutics Corp.

Company-level read

Ticker impact

$UTHRBearishMedium confidence
Context

Form 4 shows CEO/Chairperson sold $4.9M of shares via 10b5‑1 plan, reducing holdings to 324,443 shares.

Expected impact

Potential short‑term pressure on UTHR price, modest downside risk.

Evidence & confidence

Sale size is material for a mid‑cap biotech; executed under a pre‑arranged plan but still noteworthy for traders.

Market effects

Sector

May weigh on biotech sector sentiment if similar insider sales appear.

Regional

Limited to U.S. market; no broader regional effect.

Global

Minimal global impact; primarily relevant to UTHR investors.

Counterpoint

What could challenge this read

Sale was pre‑arranged under 10b5‑1, possibly unrelated to company outlook.

Key entities

  • company
    United Therapeutics Corp

    NASDAQ‑listed biotech firm.

  • person
    Martine A. Rothblatt

    Chairperson & CEO of United Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

UTHR insider trading history →

Related articles

SEP 10
$UTHRMed

Is United Therapeutics (UTHR) A Bargain Following Its Tyvaso FDA Acceptance?

United Therapeutics (UTHR) is under scrutiny after the FDA accepted its supplemental New Drug Application for Tyvaso in idiopathic pulmonary fibrosis. The company's stock has seen short-term declines, but long-term returns remain strong. Analysts suggest UTHR may be undervalued, with a fair value estimate of $665.23, citing its drug pipeline and innovation. However, risks include potential trial disappointments and competition.

simplywall.st2 min
SEP 9
$UTHRMed

United Therapeutics at Cantor healthcare conference: fibrosis push widens

United Therapeutics (UTHR) announced a strategic shift toward pulmonary fibrosis at the Cantor Fitzgerald Global Healthcare Conference, aiming for a 10-fold market expansion. The company presented strong clinical data for nebulized Tyvaso, with FDA review expected by April 2027. Management also announced a $500M stock repurchase and plans for 14 product launches through 2029, including new Tyvaso formulations and ralinepag products. The company projects a significant revenue opportunity in the p

investing.com3 min
SEP 9
$UTHRMedAI 8/10

Therapeutics Stocks Q2 Teardown: United Therapeutics (NASDAQ:UTHR) Vs The Rest

United Therapeutics (UTHR) stock rose 4.3% post-earnings, trading at $214.36. Myriad Genetics (MYGN) reported $190.7M revenue, down 10.5% YoY, missing estimates, and guidance fell short, causing a 40.9% stock drop to $3.18. Gilead Sciences (GILD) reported $7.8B revenue, up 10.2% YoY, beating estimates, with stock up 8.1% to $146.16. Novavax (NVAX) reported $56.7M revenue, down 76.3% YoY, but beat estimates, with stock up 32.2% to $10.18.

finance.yahoo.com3 min